{"corpus_id":32544246,"paper_sha":"d283d0f3a1f63a1eaa78ea2d7208fd5e581df494","doi":"10.1056/NEJMOA003199","arxiv_id":null,"pmid":11752357,"pmcid":null,"mag_id":2011327495,"dblp_id":null,"acl_id":null,"title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.","year":2001,"publication_date":"2001-12-20","venue":"New England Journal of Medicine","journal":{"name":"The New England journal of medicine","pages":"\n          1809-17\n        ","volume":"345 25"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial","Journal Article","Randomized Controlled Trial","Research Support, U.S. Gov't, P.H.S."],"s2_fields_of_study":["Medicine"],"reference_count":42,"citation_count":728,"influential_citation_count":9,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Acetaminophen","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D000082"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Analgesics, Non-Narcotic","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D018712"},{"d":"Anti-Inflammatory Agents, Non-Steroidal","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D000894"},{"d":"Aspirin","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":false,"ui":"Q000037"},{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D001241"},{"d":"Cross-Over Studies","mj":false,"ui":"D018592"},{"d":"Cyclooxygenase 1","mj":false,"ui":"D051545"},{"d":"Cyclooxygenase 2","mj":false,"ui":"D051546"},{"d":"Cyclooxygenase 2 Inhibitors","mj":false,"ui":"D052246"},{"d":"Cyclooxygenase Inhibitors","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D016861"},{"d":"Diclofenac","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D004008"},{"d":"Dinoprostone","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D015232"},{"d":"Drug Interactions","mj":false,"ui":"D004347"},{"d":"Drug Therapy, Combination","mj":false,"ui":"D004359"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Ibuprofen","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D007052"},{"d":"Isoenzymes","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":true,"ui":"Q000037"}],"ui":"D007527"},{"d":"Lactones","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D007783"},{"d":"Membrane Proteins","mj":false,"ui":"D008565"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Platelet Aggregation","mj":false,"qs":[{"q":"drug effects","mj":true,"ui":"Q000187"}],"ui":"D010974"},{"d":"Platelet Aggregation Inhibitors","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D010975"},{"d":"Prostaglandin-Endoperoxide Synthases","mj":false,"ui":"D011451"},{"d":"Sulfones","mj":false,"ui":"D013450"},{"d":"Thromboxane B2","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D013929"}],"chemicals":[{"n":"Analgesics, Non-Narcotic","ui":"D018712","reg":"0"},{"n":"Anti-Inflammatory Agents, Non-Steroidal","ui":"D000894","reg":"0"},{"n":"Cyclooxygenase 2 Inhibitors","ui":"D052246","reg":"0"},{"n":"Cyclooxygenase Inhibitors","ui":"D016861","reg":"0"},{"n":"Isoenzymes","ui":"D007527","reg":"0"},{"n":"Lactones","ui":"D007783","reg":"0"},{"n":"Membrane Proteins","ui":"D008565","reg":"0"},{"n":"Platelet Aggregation Inhibitors","ui":"D010975","reg":"0"},{"n":"Sulfones","ui":"D013450","reg":"0"},{"n":"rofecoxib","ui":"C116926","reg":"0QTW8Z7MCR"},{"n":"Diclofenac","ui":"D004008","reg":"144O8QL0L1"},{"n":"Acetaminophen","ui":"D000082","reg":"362O9ITL9D"},{"n":"Thromboxane B2","ui":"D013929","reg":"54397-85-2"},{"n":"Cyclooxygenase 1","ui":"D051545","reg":"EC 1.14.99.1"},{"n":"Cyclooxygenase 2","ui":"D051546","reg":"EC 1.14.99.1"},{"n":"PTGS1 protein, human","ui":"C496511","reg":"EC 1.14.99.1"},{"n":"PTGS2 protein, human","ui":"C496540","reg":"EC 1.14.99.1"},{"n":"Prostaglandin-Endoperoxide Synthases","ui":"D011451","reg":"EC 1.14.99.1"},{"n":"Dinoprostone","ui":"D015232","reg":"K7Q1JQR04M"},{"n":"Aspirin","ui":"D001241","reg":"R16CO5Y76E"},{"n":"Ibuprofen","ui":"D007052","reg":"WK2XYI10QM"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa003199?articleTools=true","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/d283d0f3a1f63a1eaa78ea2d7208fd5e581df494","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies METHODS: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily) RESULTS: Serum thromboxane B(2) levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B(2) formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin CONCLUSIONS: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.","claims":[{"public_id":"cl_2d34e8b266c325fccd28300ce2edffcf","status":"active","text":"Aspirin taken before a single daily dose of ibuprofen, acetaminophen, or rofecoxib maximally inhibits serum thromboxane B2 levels and platelet aggregation 24 hours after dosing on day 6.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2d34e8b266c325fccd28300ce2edffcf"},{"public_id":"cl_7139a125a9499c3fe3d3c46f44c4b04d","status":"active","text":"Concurrent ibuprofen may limit the cardioprotective effects of aspirin in patients with increased cardiovascular risk.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7139a125a9499c3fe3d3c46f44c4b04d"},{"public_id":"cl_5e6746fe07869c6cf1757e4f0c430b20","status":"active","text":"Ibuprofen given before aspirin blocks aspirin-induced inhibition of serum thromboxane B2 formation and platelet aggregation.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5e6746fe07869c6cf1757e4f0c430b20"},{"public_id":"cl_bb9a8774c2adde58a8c6fd5ff14678d3","status":"active","text":"Rofecoxib, acetaminophen, and diclofenac do not affect the pharmacodynamics of aspirin when coadministered.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_bb9a8774c2adde58a8c6fd5ff14678d3"}],"concepts":[{"public_id":"co_09393771af2fc804b1c57f079d13a2b2","status":"active","name":"pharmacodynamics of aspirin","description":"The drug effect profile of aspirin on platelet inhibition and thromboxane suppression.","types":["pharmacology"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_09393771af2fc804b1c57f079d13a2b2"},{"public_id":"co_19c02656822166733a79838d026ed540","status":"active","name":"aspirin","description":"A low-dose acetylsalicylic acid used here to assess antiplatelet effects.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_19c02656822166733a79838d026ed540"},{"public_id":"co_1fc70ad70f61e444c29866e33f69e312","status":"active","name":"platelet aggregation","description":"The clumping response of platelets measured as an indicator of antiplatelet effect.","types":["measurement"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1fc70ad70f61e444c29866e33f69e312"},{"public_id":"co_2720309fb53223e0ca1a41bea0732434","status":"active","name":"rofecoxib","description":"A cyclooxygenase-2 inhibitor evaluated for interaction with aspirin.","types":["drug","cyclooxygenase-2 inhibitor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2720309fb53223e0ca1a41bea0732434"},{"public_id":"co_3b5d6e2397a605a05dc71caf83375f1c","status":"active","name":"serum thromboxane B2","description":"A serum marker used as an index of platelet cyclooxygenase-1 activity.","types":["biomarker"],"aliases":["TXB2"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3b5d6e2397a605a05dc71caf83375f1c"},{"public_id":"co_5d3d8231143634eac6c44d747ac875c9","status":"active","name":"cardiovascular risk","description":"The baseline risk of cardiovascular events in patients receiving antiplatelet therapy.","types":["risk factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5d3d8231143634eac6c44d747ac875c9"},{"public_id":"co_906d82be4fc41c89cd852378332473c1","status":"active","name":"diclofenac","description":"A delayed-release nonsteroidal anti-inflammatory drug evaluated with aspirin.","types":["drug","nonsteroidal anti-inflammatory drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_906d82be4fc41c89cd852378332473c1"},{"public_id":"co_99ad4da9aefa276665bc84a371da53e6","status":"active","name":"cardioprotective effects of aspirin","description":"The cardiovascular protective benefit attributed to aspirin's antiplatelet action.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_99ad4da9aefa276665bc84a371da53e6"},{"public_id":"co_b7abc7c8b1797ddb688a2c0c12c1df32","status":"active","name":"ibuprofen","description":"A nonsteroidal anti-inflammatory drug used here in single or multiple daily dosing.","types":["drug","nonsteroidal anti-inflammatory drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b7abc7c8b1797ddb688a2c0c12c1df32"},{"public_id":"co_c6974f622b57ed945a1a8868bd8e8b3a","status":"active","name":"acetaminophen","description":"A commonly prescribed analgesic evaluated for interaction with aspirin.","types":["drug"],"aliases":["paracetamol"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c6974f622b57ed945a1a8868bd8e8b3a"},{"public_id":"co_d354bcc41f7b769fb49bcdf70cc1d60c","status":"active","name":"cyclooxygenase-1","description":"An enzyme in platelets whose activity is indexed by serum thromboxane B2.","types":["enzyme"],"aliases":["COX-1"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d354bcc41f7b769fb49bcdf70cc1d60c"}],"external_ids":{"DOI":"10.1056/NEJMOA003199","ArXiv":null,"PubMed":11752357,"PubMedCentral":null,"MAG":2011327495,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa003199?articleTools=true","landing_url":"https://www.semanticscholar.org/paper/d283d0f3a1f63a1eaa78ea2d7208fd5e581df494","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":637308,"paper_uid":"149b19e8-454f-4fe4-b52a-81d687ad711e","canonical_identity":{"paper_id":637308,"paper_uid":"149b19e8-454f-4fe4-b52a-81d687ad711e","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/32544246"}